MedTrace Logo

The Risk of Second Primary Gastrointestinal Malignancies Following Primary Gastrointestinal Carcinoid Tumors: a SEER Based Study 2000-2022

NCT07291752 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93481

Last updated 2025-12-18

No results posted yet for this study

Summary

Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course. Carcinoid tumors are the most common gastrointestinal (GI) neuroendocrine tumors. The most common sites of GI carcinoids are small intestine accounting for 45%, rectum (20%), appendix (17%), colon (11%), and stomach (7%). Some studies reported an association between neuroendocrine tumors and multiple malignancies. However, the presence of neuroendocrine tumors combined with multiple primary GI tumors is considered an exotic event in the literature with only few case studies and case series. So the aim of this study is to assess the risk of GI malignancies following primary GI carcinoids.

Conditions

  • Carcinoid Tumor
  • Second Primary Malignant Neoplasm

Sponsors & Collaborators

  • Suez Canal University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-12-01
Primary Completion
2022-12-30
Completion
2022-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07291752 on ClinicalTrials.gov